Details
Title
Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features
Author
Flanagan, Dustin J. 1
; Amirkhah, Raheleh 2
; Vincent, David F. 3 ; Gunduz, Nuray 3 ; Gentaz, Pauline 3 ; Cammareri, Patrizia 3 ; McCooey, Aoife J. 2 ; McCorry, Amy M. B. 2 ; Fisher, Natalie C. 2 ; Davis, Hayley L. 4
; Ridgway, Rachel A. 3
; Lohuis, Jeroen 5 ; Leach, Joshua D. G. 6 ; Jackstadt, Rene 7 ; Gilroy, Kathryn 3 ; Mariella, Elisa 8 ; Nixon, Colin 3
; Clark, William 3 ; Hedley, Ann 9
; Markert, Elke K. 6 ; Strathdee, Douglas 3
; Bartholin, Laurent 10
; Redmond, Keara L. 2 ; Kerr, Emma M. 2
; Longley, Daniel B. 2 ; Ginty, Fiona 11 ; Cho, Sanghee 11 ; Coleman, Helen G. 12 ; Loughrey, Maurice B. 13 ; Bardelli, Alberto 8
; Maughan, Timothy S. 14 ; Campbell, Andrew D. 3
; Lawler, Mark 2 ; Leedham, Simon J. 4 ; Barry, Simon T. 15
; Inman, Gareth J. 6
; van Rheenen, Jacco 5
; Dunne, Philip D. 16
; Sansom, Owen J. 6
1 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); Monash University, Department of Biochemistry and Molecular Biology, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Cancer Program, Biomedicine Discovery Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
2 Queen’s University Belfast, The Patrick G. Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
3 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196)
4 University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 Oncode Institute, The Netherlands Cancer Institute, Department of Molecular Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393)
6 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Glasgow, Institute of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
7 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH) and Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany (GRID:grid.482664.a)
8 University of Torino, Department of Oncology, Torino, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
9 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Newcastle upon Tyne, Newcastle, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212)
10 INSERM Centre de Recherche en Cancérologie de Lyon, Lyon, France (GRID:grid.462282.8) (ISNI:0000 0004 0384 0005)
11 GE Global Research Center, Niskayuna, USA (GRID:grid.418143.b) (ISNI:0000 0001 0943 0267)
12 Queen’s University Belfast, The Patrick G. Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Queen’s University Belfast, Centre for Public Health, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
13 Queen’s University Belfast, The Patrick G. Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Queen’s University Belfast, Centre for Public Health, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Belfast Health and Social Care Trust, Department of Cellular Pathology, Belfast, UK (GRID:grid.412915.a) (ISNI:0000 0000 9565 2378)
14 University of Oxford, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
15 Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
16 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); Queen’s University Belfast, The Patrick G. Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
; Amirkhah, Raheleh 2
; Vincent, David F. 3 ; Gunduz, Nuray 3 ; Gentaz, Pauline 3 ; Cammareri, Patrizia 3 ; McCooey, Aoife J. 2 ; McCorry, Amy M. B. 2 ; Fisher, Natalie C. 2 ; Davis, Hayley L. 4
; Ridgway, Rachel A. 3
; Lohuis, Jeroen 5 ; Leach, Joshua D. G. 6 ; Jackstadt, Rene 7 ; Gilroy, Kathryn 3 ; Mariella, Elisa 8 ; Nixon, Colin 3
; Clark, William 3 ; Hedley, Ann 9
; Markert, Elke K. 6 ; Strathdee, Douglas 3
; Bartholin, Laurent 10
; Redmond, Keara L. 2 ; Kerr, Emma M. 2
; Longley, Daniel B. 2 ; Ginty, Fiona 11 ; Cho, Sanghee 11 ; Coleman, Helen G. 12 ; Loughrey, Maurice B. 13 ; Bardelli, Alberto 8
; Maughan, Timothy S. 14 ; Campbell, Andrew D. 3
; Lawler, Mark 2 ; Leedham, Simon J. 4 ; Barry, Simon T. 15
; Inman, Gareth J. 6
; van Rheenen, Jacco 5
; Dunne, Philip D. 16
; Sansom, Owen J. 6
1 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); Monash University, Department of Biochemistry and Molecular Biology, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Cancer Program, Biomedicine Discovery Institute, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857)
2 Queen’s University Belfast, The Patrick G. Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
3 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196)
4 University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 Oncode Institute, The Netherlands Cancer Institute, Department of Molecular Pathology, Amsterdam, The Netherlands (GRID:grid.430814.a) (ISNI:0000 0001 0674 1393)
6 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Glasgow, Institute of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
7 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH) and Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany (GRID:grid.482664.a)
8 University of Torino, Department of Oncology, Torino, Italy (GRID:grid.7605.4) (ISNI:0000 0001 2336 6580)
9 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Newcastle upon Tyne, Newcastle, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212)
10 INSERM Centre de Recherche en Cancérologie de Lyon, Lyon, France (GRID:grid.462282.8) (ISNI:0000 0004 0384 0005)
11 GE Global Research Center, Niskayuna, USA (GRID:grid.418143.b) (ISNI:0000 0001 0943 0267)
12 Queen’s University Belfast, The Patrick G. Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Queen’s University Belfast, Centre for Public Health, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
13 Queen’s University Belfast, The Patrick G. Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Queen’s University Belfast, Centre for Public Health, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521); Belfast Health and Social Care Trust, Department of Cellular Pathology, Belfast, UK (GRID:grid.412915.a) (ISNI:0000 0000 9565 2378)
14 University of Oxford, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
15 Bioscience, Oncology R&D, AstraZeneca, Cambridge, UK (GRID:grid.417815.e) (ISNI:0000 0004 5929 4381)
16 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); Queen’s University Belfast, The Patrick G. Johnston Centre for Cancer Research, Belfast, UK (GRID:grid.4777.3) (ISNI:0000 0004 0374 7521)
Pages
522
Publication year
2023
Publication date
2023
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2771199319
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.